High ROIC Stocks
ADMA is currently part of our High ROIC Stocks screen, indicating it generates strong returns on invested capital.
ADMA BIOLOGICS INC (ADMA) Stock Price & Overview
NASDAQ:ADMA • US0008991046
Current stock price
9.19 USD
+0.08 (+0.88%)
At close:
9.249 USD
+0.06 (+0.64%)
After Hours:
The current stock price of ADMA is 9.19 USD. Today ADMA is up by 0.88%. In the past month the price decreased by -41.46%. In the past year, price decreased by -48.97%.
ADMA Key Statistics
52-Week Range7.2101 - 25.67
Current ADMA stock price positioned within its 52-week range.
1-Month Range7.2101 - 16.385
Current ADMA stock price positioned within its 1-month range.
- Market Cap
- 2.189B
- P/E
- 15.32
- Fwd P/E
- 9.96
- EPS (TTM)
- 0.60
- Dividend Yield
- N/A
ADMA Stock Performance
Today
+0.88%
1 Week
+10.86%
1 Month
-41.47%
3 Months
-48.60%
Longer-term
6 Months -37.31%
1 Year -48.97%
2 Years +40.95%
3 Years +174.33%
5 Years +368.88%
10 Years +34.36%
ADMA Stock Chart
ADMA Stock Screens
ADMA currently appears in the following ChartMill screener lists.
RSI Oversold Stocks
ADMA is flagged as RSI oversold, meaning recent selling pressure has pushed momentum to extreme levels that may lead to a short-term rebound.
ADMA Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to ADMA. When comparing the yearly performance of all stocks, ADMA is a bad performer in the overall market: 94.76% of all stocks are doing better.
Chartmill TA Rating
Chartmill Setup Rating
ADMA Fundamental Analysis
ChartMill assigns a fundamental rating of 7 / 10 to ADMA. Both the health and profitability get an excellent rating, making ADMA a very profitable company, without any liquidiy or solvency issues.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
ADMA Earnings
On February 25, 2026 ADMA reported an EPS of 0.2 and a revenue of 139.16M. The company beat EPS expectations (5.99% surprise) and missed revenue expectations (-2.13% surprise).
Next Earnings DateMay 5, 2026
Last Earnings DateFeb 25, 2026
PeriodQ4 / 2025
EPS Reported$0.20
Revenue Reported139.163M
EPS Surprise 5.99%
Revenue Surprise -2.13%
ADMA Forecast & Estimates
9 analysts have analysed ADMA and the average price target is 26.18 USD. This implies a price increase of 184.87% is expected in the next year compared to the current price of 9.19.
For the next year, analysts expect an EPS growth of 53.85% and a revenue growth 24.85% for ADMA
Analysts
Analysts80
Price Target26.18 (184.87%)
EPS Next Y53.85%
Revenue Next Year24.85%
ADMA Groups
Sector & Classification
ADMA Financial Highlights
Over the last trailing twelve months ADMA reported a non-GAAP Earnings per Share(EPS) of 0.6. The EPS increased by 20% compared to the year before.
Income Statements
Revenue(TTM)510.17M
Net Income(TTM)146.93M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 28.8% | ||
| ROA | 23.54% | ||
| ROE | 30.78% | ||
| Debt/Equity | 0.15 |
Chartmill High Growth Momentum
EPS Q2Q%42.86%
Sales Q2Q%18.39%
EPS 1Y (TTM)20%
Revenue 1Y (TTM)19.63%
ADMA Ownership
Ownership
Inst Owners93.28%
Shares238.16M
Float228.86M
Ins Owners2.53%
Short Float %11.29%
Short Ratio4.95
ADMA Competitors/Peers
The largest stocks on the US markets in the "Biotechnology" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.07 | 369.265B | ||
| AMGN | AMGEN INC | 15.24 | 187.564B | ||
| GILD | GILEAD SCIENCES INC | 15.81 | 173.439B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.63 | 111.445B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.3 | 80.543B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 42.73 | 42.286B | ||
| INSM | INSMED INC | N/A | 35.012B | ||
| NTRA | NATERA INC | N/A | 29.477B | ||
| BIIB | BIOGEN INC | 11.03 | 26.026B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.91 | 24.756B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.643B | ||
| MRNA | MODERNA INC | N/A | 19.431B | ||
| INCY | INCYTE CORP | 12.53 | 19.091B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About ADMA
Company Profile
ADMA Biologics, Inc. operates as a biopharmaceutical company, which is engaged in manufacturing, marketing, and developing specialty plasma-derived biologics. The company is headquartered in Ramsey, New Jersey and currently employs 647 full-time employees. The company went IPO on 2013-10-17. The firm manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: ASCENIV (immune globulin intravenous, human-slra 10% liquid) for the treatment of primary humoral immunodeficiency (PI); BIVIGAM (immune globulin intravenous, human) for the treatment of PI; and NABI-HB (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. Through its ADMA BioCenters subsidiary, the Company also operates as an FDA-approved source plasma collector in the United States, which provides its blood plasma for the manufacture of its products.
Company Info
IPO: 2013-10-17
ADMA BIOLOGICS INC
465 State Route 17
Ramsey NEW JERSEY 07446 US
CEO: Adam S. Grossman
Employees: 647
Phone: 12014785552
ADMA BIOLOGICS INC / ADMA FAQ
What does ADMA do?
ADMA Biologics, Inc. operates as a biopharmaceutical company, which is engaged in manufacturing, marketing, and developing specialty plasma-derived biologics. The company is headquartered in Ramsey, New Jersey and currently employs 647 full-time employees. The company went IPO on 2013-10-17. The firm manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: ASCENIV (immune globulin intravenous, human-slra 10% liquid) for the treatment of primary humoral immunodeficiency (PI); BIVIGAM (immune globulin intravenous, human) for the treatment of PI; and NABI-HB (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. Through its ADMA BioCenters subsidiary, the Company also operates as an FDA-approved source plasma collector in the United States, which provides its blood plasma for the manufacture of its products.
What is the current price of ADMA stock?
The current stock price of ADMA is 9.19 USD. The price increased by 0.88% in the last trading session.
What is the dividend status of ADMA BIOLOGICS INC?
ADMA does not pay a dividend.
What is the ChartMill technical and fundamental rating of ADMA stock?
ADMA has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 7 out of 10.
How is the market expecting ADMA stock to perform?
9 analysts have analysed ADMA and the average price target is 26.18 USD. This implies a price increase of 184.87% is expected in the next year compared to the current price of 9.19.
Can you provide the market cap for ADMA BIOLOGICS INC?
ADMA BIOLOGICS INC (ADMA) has a market capitalization of 2.19B USD. This makes ADMA a Mid Cap stock.
Can you provide the ownership details for ADMA stock?
You can find the ownership structure of ADMA BIOLOGICS INC (ADMA) on the Ownership tab.